Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yang, S.-H.
Right arrow Articles by Hsu, K.-T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, S.-H.
Right arrow Articles by Hsu, K.-T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 2017-2019
© 2002 European Renal Association-European Dialysis and Transplant Association

Case Reports

The successful treatment of renal-vein thrombosis by low-molecular-weight heparin in a steroid-sensitive nephrotic patient

Shih-Hsien Yang1,, Chih-Hsiung Lee1, Sheung-Fat Ko2, Jin-Bor Chen1, Feng-Rong Chung1 and Kuo-Tai Hsu1

Department of Internal Medicine, 1 Division of Nephrology and 2 Department of Radiology, Chang Gung Memorial Hospital at Kaohsiung, Taiwan, ROC

Keywords: low-molecular-weight heparin; renal-vein thrombosis; steroid sensitivity; thrombolytic therapy

The first 10% of the full text of this article appears below.



   Introduction
 
Patients with nephrotic syndrome frequently have renal-vein thrombosis (RVThromb) without overt clinical manifestations. At the onset of the condition only 10% of these patients have acute signs and symptoms such as flank pain, haematuria, proteinuria and a rapid decline of renal function [1]. Patients experiencing severe flank pain, a rapid deterioration of renal function and concomitant pulmonary emboli or multiple thrombi have been successfully managed with thrombolytic agents [3], despite the fact that the risk associated with thrombolytic therapy seems to be greater than that of anticoagulant therapy, which would appear to be a more appropriate choice of treatment. Since low-molecular-weight heparins (LMWHep) have a longer half-life and better bioavailability than unfractionated heparin, they are widely used for treating many clinical conditions [4]. . . . [Full Text of this Article]



   Case
 


   Discussion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?